NAICS 325411 Quarterly Industry Report
Medicinal and Botanical Manufacturing
Comprehensive industry research for valuation professionals, business owners, buyers, and lenders
NAICS Code: 325411Sector: 32Updated: Q1 2026
About This Report
This Fair Market Value industry report for NAICS 325411 provides business owners, acquirers, and financial advisors with data-driven valuation insights for the medicinal and botanical manufacturing sector, drawing on data from the U.S. Census Bureau[5] and FDA[9] pharmaceutical manufacturing registration statistics. Additional data is drawn from Bureau of Labor Statistics[10].. The report aggregates transaction multiples, financial benchmarks, and market trends specific to NAICS 325411 establishments, supporting buy-sell agreements, succession planning, SBA-financed acquisitions, and litigation support engagements.
Industry Snapshot
Key metrics for the medicinal and botanical manufacturing industry.
Industry Definition & Overview
Medicinal and Botanical Manufacturing (NAICS 325411) encompasses establishments primarily engaged in manufacturing uncompounded medicinal chemicals and their derivatives for use by pharmaceutical preparation manufacturers, as well as grading, grinding, and milling uncompounded botanicals. Products include active pharmaceutical ingredients, vegetable alkaloids such as caffeine, codeine, and morphine, botanical extracts, and bulk medicinal chemicals processed from natural and synthetic sources. According to the U.S. Census Bureau[5], the industry generated over $11.4 billion in revenue through facilities that supply the critical upstream inputs consumed by downstream pharmaceutical dosage form manufacturers and dietary supplement producers.
The industry operates at the intersection of chemical synthesis and natural product extraction, with manufacturers producing bulk drug substances through multi-step organic synthesis, fermentation, extraction from plant materials, and biotechnology processes. Import competition is substantial, with the International Trade Administration[6] reporting over $11.3 billion in medicinal and botanical imports primarily from Ireland, China, and India, reflecting the global nature of pharmaceutical active ingredient supply chains. The Bureau of Labor Statistics[7] identifies production roles including process chemists managing multi-step synthesis reactions, quality control analysts performing pharmacopeial testing, botanical extraction operators, cGMP compliance specialists ensuring FDA manufacturing standards adherence, and regulatory affairs professionals managing Drug Master File submissions.
Per the SBA Office of Advocacy[8], the industry includes large multinational pharmaceutical companies operating vertically integrated active ingredient production alongside smaller contract manufacturing organizations, botanical processors, and specialty API manufacturers serving generic pharmaceutical customers. Growing emphasis on domestic pharmaceutical supply chain security following pandemic-era shortages has increased interest in reshoring active ingredient manufacturing capacity to the United States.
What's Included in This Industry
- Valuation multiples benchmarked to medicinal and botanical manufacturing operations
- Revenue and EBITDA trends for domestic API and botanical processing facilities
- SBA lending data and financing terms for NAICS 325411 businesses
- Comparable transaction data from recent API manufacturer and CDMO acquisitions
- Industry risk factors including FDA compliance, import competition, and supply chain security
- Workforce composition and labor cost benchmarks for cGMP manufacturing operations
- Regional market analysis covering pharmaceutical manufacturing clusters
- Capital expenditure benchmarks for synthesis reactors and extraction equipment
- Growth projections tied to pharmaceutical reshoring and botanical supplement demand
- Owner compensation and discretionary earnings benchmarks
NAICS Classification Hierarchy
| Level | Description | Code |
|---|---|---|
| Subsector | Chemical Manufacturing | 325 |
| Industry Group | Pharmaceutical and Medicine Manufacturing | 3254 |
| NAICS Industry | Pharmaceutical and Medicine Manufacturing | 32541 |
| National Industry | Medicinal and Botanical Manufacturing | 325411 |
Related NAICS Codes
| Code | Description | Relationship |
|---|---|---|
| 325412 | Pharmaceutical Preparation Manufacturing | Pharmaceutical preparation manufacturers purchasing active pharmaceutical ingredients and botanical extracts for formulation into finished dosage form drug products |
| 325414 | Biological Product (except Diagnostic) Manufacturing | Biological product manufacturers sharing cGMP manufacturing infrastructure and FDA regulatory compliance frameworks with medicinal chemical manufacturing operations |
| 325199 | All Other Basic Organic Chemical Manufacturing | Basic organic chemical manufacturers producing chemical intermediates and solvents consumed as starting materials in multi-step pharmaceutical active ingredient synthesis |
| 325413 | In-Vitro Diagnostic Substance Manufacturing | In-vitro diagnostic substance manufacturers sharing pharmaceutical-grade chemical production capabilities and quality management system requirements with medicinal producers |
| 541715 | Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) | Research and development laboratories in the physical, engineering, and life sciences conducting drug discovery research that generates demand for novel API manufacturing |
| 424210 | Drugs and Druggists' Sundries Merchant Wholesalers | Drug and druggist sundries merchant wholesalers distributing bulk medicinal chemicals and botanical ingredients to pharmaceutical manufacturers and supplement producers |
Geographic Concentration
Top states by share of national establishments.
| # | State | % Est. | Total Est. |
|---|---|---|---|
| 1 | California | 16.0% | 120 |
| 2 | Colorado | 10.2% | 77 |
| 3 | Florida | 6.8% | 51 |
| 4 | Texas | 6.1% | 46 |
| 5 | New Jersey | 4.9% | 37 |
| 6 | Utah | 4.8% | 36 |
| 7 | New York | 3.9% | 29 |
| 8 | Michigan | 3.7% | 28 |
| 9 | Illinois | 3.3% | 25 |
| 10 | Massachusetts | 3.1% | 23 |
% Of Establishments
0%
16%
Source: County Business Patterns, U.S. Census Bureau[3]
SBA Lending Summary
208
Total SBA Loans
$182.2M
Total Loan Volume
$876K
Average Loan Size
11 yrs
Average Loan Term
10.14%
Average Interest Rate
1,624
Jobs Supported
Source: SBA 7(a) Program Data, U.S. Small Business Administration — FY 2025[4]
Key Insight: Medicinal and botanical manufacturers evaluating SBA financing must consider qualification under the SBA size standards[11] for NAICS 325411, which set the threshold at 1,250 employees for small business classification. The SBA 7(a) loan program[12] supports smaller API manufacturers, botanical processors, and contract manufacturing organizations acquiring operations or financing working capital for raw material procurement, while the CDC/504 loan program[13] provides long-term fixed-rate financing for cGMP-compliant reactor systems, clean room facilities, extraction equipment, and quality laboratory buildouts. Lenders evaluate FDA registration status, cGMP compliance history, and customer contract stability when structuring medicinal manufacturing loans.
Top SBA Lenders
| # | Lender | Loans | Volume | Avg Loan |
|---|---|---|---|---|
| 1 | InBank | 24 | $65.2M | $2.7M |
| 2 | Byline Bank | 8 | $40.0M | $5.0M |
| 3 | Newtek Bank, National Association | 24 | $16.5M | $688K |
| 4 | Central Bank | 24 | $12.0M | $500K |
| 5 | First Internet Bank of Indiana | 8 | $11.5M | $1.4M |
Frequently Asked Questions
Common questions about this industry.
What is the typical valuation multiple for a medicinal chemical manufacturer?
Medicinal and botanical manufacturers typically trade at 6x to 12x EBITDA, with contract development and manufacturing organizations and specialty API producers commanding premium multiples. Per U.S. Census Bureau[5] data, valuations reflect FDA facility approval status, customer pipeline visibility, and proprietary synthesis capabilities.
What SBA loan options are available for medicinal manufacturing businesses?
The SBA[11] sets the small business threshold at 1,250 employees for NAICS 325411. SBA financing supports smaller contract manufacturers, botanical processors, and specialty API companies, with 7(a) loans for acquisitions and 504 loans for cGMP facility investments.
What FDA requirements affect medicinal chemical manufacturers?
The FDA[9] requires drug substance manufacturers to register facilities, comply with current Good Manufacturing Practice regulations, and maintain Drug Master Files documenting manufacturing processes, specifications, and quality controls for each active pharmaceutical ingredient produced.
How does import competition affect domestic API manufacturers?
Over 80% of active pharmaceutical ingredients consumed in the U.S. are imported, with China and India supplying the majority of generic API production. Per the International Trade Administration[6], the $11.3 billion import market creates pricing pressure on domestic producers while also motivating reshoring investment for supply chain security.
What are the growth drivers for medicinal chemical manufacturing?
Pharmaceutical supply chain reshoring initiatives, biosimilar API production, and growing demand for botanical and dietary supplement ingredients drive industry growth. Per the FDA[9], federal incentives for domestic pharmaceutical manufacturing and pandemic preparedness programs support new capacity investment.
How does cGMP compliance affect business valuations?
FDA-inspected facilities with clean compliance histories command premium valuations, as regulatory approval represents a barrier to entry worth years of investment and documentation. Per the FDA[9], warning letters or consent decree histories materially reduce acquisition valuations due to remediation costs and customer confidence impacts.
What workforce challenges do medicinal manufacturers face?
The Bureau of Labor Statistics[7] reports strong demand for process chemists, quality assurance specialists, and cGMP compliance professionals across pharmaceutical manufacturing. Competition from pharmaceutical preparation manufacturers and biotechnology companies for trained scientists creates recruitment challenges.
How does the botanical supplement market affect this industry?
Growing consumer demand for herbal supplements and botanical products has expanded the market for NAICS 325411 botanical processors. Per the FDA[9], dietary supplement cGMP requirements under 21 CFR Part 111 create quality standards that favor established botanical processors over informal herb grinding operations.
Sources & References
Government datasets and editorial sources used in this report.
- [1]U.S. Bureau of Labor Statistics, Quarterly Census of Employment and Wages bls.gov
- [2]U.S. Census Bureau, Economic Census census.gov
- [3]U.S. Census Bureau, County Business Patterns census.gov
- [4]U.S. Small Business Administration, SBA 7(a) Loan Program Data data.sba.gov
- [5]U.S. Census Bureau census.gov
- [6]International Trade Administration trade.gov
- [7]Bureau of Labor Statistics bls.gov
- [8]SBA Office of Advocacy advocacy.sba.gov
- [9]FDA fda.gov
- [10]Bureau of Labor Statistics bls.gov
- [11]SBA size standards sba.gov
- [12]SBA 7(a) loan program sba.gov
- [13]CDC/504 loan program sba.gov
Disclaimer
This publication has been prepared by Fair Market Value (“Fair Market Value”) for informational purposes only. It is provided on an “as-is” and “as available” basis. Fair Market Value makes no representations or warranties, express or implied, regarding the merchantability, fitness for a particular purpose, completeness, or accuracy of the data or information contained herein. This publication is not intended to be, and should not be construed as, professional financial, legal, tax, or investment advice. Users should consult with qualified professionals before making any financial or business decisions based on the information presented.
To the extent permitted by law, Fair Market Value disclaims all liability for loss or damage, direct and indirect, suffered or incurred by any person resulting from the use of, or reliance upon, the data in this publication.
Copyright © 2026 Fair Market Value. All rights reserved. All data, information, articles, graphs, and content contained in this publication are copyrighted works and Fair Market Value hereby reserves all rights. No part of this publication may be copied, reproduced, republished, uploaded to a third party, or distributed without the prior written permission of Fair Market Value.